endo-3-(8-azabicyclo[3.2.1]octan-3-yl)-2-methyl-3H-imidazo[4,5-b]pyridine | 716358-87-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并吡啶类
• 英文名称: endo-3-(8-azabicyclo[3.2.1]octan-3-yl)-2-methyl-3H-imidazo[4,5-b]pyridine
• 英文别名: endo-1-[(1R,5S)-8-azabicyclo[3.2.1]oct-3-yl]-2-methyl-3H-imidazo[4,5-b]pyridine
• CAS: 716358-87-1
• 化学式: C₁₄H₁₈N₄
• 分子量: 242.324
• InChiKey: CDPIESNFWPHUAD-GDNZZTSVSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  18.0
• 可旋转键数：
  1.0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  42.74
• 氢给体数：
  1.0
• 氢受体数：
  4.0

反应信息

• 作为反应物：
  描述：

  endo-3-(8-azabicyclo[3.2.1]octan-3-yl)-2-methyl-3H-imidazo[4,5-b]pyridine 、 (S)-4-((S)-4-benzyl-2-oxooxazolidin-3-yl)-4-oxo-3-phenylbutanal 在 三乙酰氧基硼氢化钠 、 溶剂黄146 作用下， 以 1,2-二氯乙烷 为溶剂， 生成 (S)-4-benzyl-3-((S)-4-((1R,3S,5S)-3-(2-methyl-3H-imidazo[4,5-b]pyridin-3-yl)-8-azabicyclo[3.2.1]octan-8-yl)-2-phenylbutanoyl)oxazolidin-2-one
  参考文献：
  名称：

  Discovery of novel (S)-α-phenyl-γ-amino butanamide containing CCR5 antagonists via functionality inversion approach

  摘要：

  By using functionality inversion approach, we identified a new scaffold containing (S)-alpha-phenyl-gamma-amino butanamide as CCR5 antagonists derived from the 1,3-propanediamine carboxamide pharmacophore protocol. The (2S)-2-phenyl-4-(8-aza-bicyclo[3.2.1]octan-8-yl)-butanamide derivatives display significantly high potency to antagonize CCR5 receptor with nanomolar IC50 values. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.02.023
• 作为产物：
  描述：

  1,1-dimethylethyl endo-3-[(phenylmethyl)amino]-8-azabicyclo[3.2.1]octane-8-carboxylate 在 盐酸 、 palladium 10% on activated carbon 、 氢气 、 camphor-10-sulfonic acid 、 N,N-二异丙基乙胺 作用下， 以 1,4-二氧六环 、 N-甲基吡咯烷酮 、 甲醇 、 乙醇 、 乙酸乙酯 为溶剂， 20.0~70.0 ℃ 、101.33 kPa 条件下， 反应 35.0h， 生成 endo-3-(8-azabicyclo[3.2.1]octan-3-yl)-2-methyl-3H-imidazo[4,5-b]pyridine
  参考文献：
  名称：

  Novel 4,4-Disubstituted Piperidine-Based C–C Chemokine Receptor-5 Inhibitors with High Potency against Human Immunodeficiency Virus-1 and an Improved human Ether-a-go-go Related Gene (hERG) Profile

  摘要：

  We recently described (J. Med. Chem. 2008, 51, 6538-6546) a novel class of CCR5 antagonists with strong anti-HIV potency. Herein, we detail SAR converting leads 1 and 2 to druglike molecules. The pivotal structural motif enabling this transition was the secondary sulfonamide substituent. Further fine-tuning of the substituent pattern in the sulfonamide paved the way to enhancing potency and bioavailability and minimizing hERG inhibition, resulting in discovery of clinical compound 122 (GSK163929).

  DOI：

  10.1021/jm200279v

文献信息

• Efficient synthesis and identification of novel propane-1,3-diamino bridged CCR5 antagonists with variation on the basic center carrier
  作者：Xing Fan、Hu-Shan Zhang、Li Chen、Ya-Qiu Long

  DOI：10.1016/j.ejmech.2010.03.003

  日期：2010.7

  perazine-bridged CCR5 antagonists were designed and synthesized via an efficient convergent synthesis strategy, with focus on the optimal choice of the basic center carrier structure. Significantly, the 4-amino-4-methylpiperidine bridged 1-acyl-1,3-propanediamine compounds were identified as a new class of nanomolar CCR5 antagonists, providing an efficient approach and novel scaffolds for further development

  通过采用基于药效团的设计和特权片段的重组，通过有效的聚合合成策略设计并合成了一系列哌啶-/-托帕烷-/哌嗪-桥连的CCR5拮抗剂，重点是基本中心载体结构的最佳选择。重要的是，4-氨基-4-甲基哌啶桥联的1-酰基-1,3-丙二胺化合物被确定为一类新型的纳摩尔CCR5拮抗剂，为有效开发CCR5抑制剂提供了有效的方法和新颖的支架。
• US7645771B2
  申请人：——

  公开号：US7645771B2

  公开（公告）日：2010-01-12